-
1.发明公开FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME 有权RINGKONDENSIERTES DERIVAT UND MEDISINISCHE ANWENDUNG DAVON
公开(公告)号：EP2343279A4
公开(公告)日：2014-08-06
申请号：EP09820583
申请日：2009-10-14
IPC分类号： C07D213/79 , A61K31/192 , A61K31/415 , A61K31/426 , A61K31/44 , A61K31/47 , A61P3/00 , A61P13/04 , A61P13/12 , A61P19/00 , A61P19/06 , C07C255/57 , C07D215/50 , C07D231/14 , C07D277/20 , C07D277/56
CPC分类号： C07C255/57 , A61K31/192 , A61K31/415 , A61K31/426 , A61K31/44 , A61K31/47 , C07C255/54 , C07D213/79 , C07D215/50 , C07D231/14 , C07D277/20 , C07D277/56
摘要： The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal plasma uric acid level and the like. The present invention relates to fused ring derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of plasma uric acid level, prodrugs thereof, salts thereof or the like. In the formula (I), X 1 and X 2 represent CH or N; ring U represents aryl or heteroaryl; m represents integral number from 0 to 2; n represents integral number from 0 to 3; R 1 represents a hydroxy group, amino or C 1-6 alkyl; R 2 represents C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl or the like.
摘要翻译： 本发明提供了可用作预防或治疗与异常血浆尿酸水平等相关的疾病的药剂的化合物。 本发明涉及具有黄嘌呤氧化酶抑制活性的由下式（I）表示的稠环衍生物，可用作预防或治疗与血浆尿酸水平异常有关的疾病，其前体药物，其盐或类似物 。 在式（I）中，X 1和X 2表示CH或N; 环U表示芳基或杂芳基; m表示0〜2的整数; n表示0〜3的整数; R 1表示羟基，氨基或C 1-6烷基; R 2表示C 1-6烷基，C 1-6烷氧基C 1-6烷基等。
-
2.发明公开
公开(公告)号：EP2133331A4
公开(公告)日：2011-06-22
申请号：EP08740194
申请日：2008-04-10
发明人： SHIMIZU KAZUO , TAKIGAWA YASUSHI , FUJIKURA HIDEKI , IIZUKA MASATO , HIRATOCHI MASAHIRO , KIKUCHI NORIHIKO
IPC分类号： C07D207/34 , A61K31/402 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K45/00 , A61P13/02 , A61P19/06 , A61P43/00 , C07D231/14 , C07D231/16 , C07D231/20 , C07D231/38 , C07D231/40 , C07D401/04 , C07D403/04
CPC分类号： A61K31/402 , A61K31/165 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K45/06 , C07D207/34 , C07D231/14 , C07D231/16 , C07D231/20 , C07D231/38 , C07D231/40 , C07D401/04 , C07D403/04 , C07D405/04 , C07D405/06 , C07D409/04 , C07D409/12 , C07D417/04 , A61K2300/00
-
公开(公告)号：EP2338887A4
公开(公告)日：2012-05-09
申请号：EP09820582
申请日：2009-10-14
IPC分类号： C07D401/04 , A61K31/427 , A61K31/443 , A61K31/4439 , A61P13/04 , A61P13/12 , A61P19/02 , A61P19/06 , A61P43/00 , C07D405/04 , C07D417/04
CPC分类号： C07D401/04 , A61K31/427 , A61K31/443 , A61K31/4439 , C07D405/04 , C07D417/04
-
公开(公告)号：EP2133332A4
公开(公告)日：2011-05-25
申请号：EP08740190
申请日：2008-04-10
发明人： SHIMIZU KAZUO , TAKIGAWA YASUSHI , FUJIKURA HIDEKI , IIZUKA MASATO , HIRATOCHI MASAHIRO , KIKUCHI NORIHIKO
IPC分类号： C07D209/42 , A61K31/404 , A61K31/407 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/5377 , A61K45/00 , A61P13/04 , A61P13/12 , A61P19/02 , A61P19/06 , A61P43/00 , C07D401/04 , C07D405/04 , C07D409/12 , C07D417/04 , C07D471/04 , C07D491/056
CPC分类号： C07D209/30 , A61K31/165 , A61K31/404 , A61K31/407 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D209/42 , C07D401/04 , C07D405/04 , C07D405/10 , C07D409/12 , C07D417/04 , C07D471/04 , C07D491/056 , A61K2300/00
-
公开(公告)号：EP1698635A4
公开(公告)日：2009-06-17
申请号：EP04807647
申请日：2004-12-16
发明人： KIKUCHI NORIHIKO , NONAKA YOSHINORI , TATANI KAZUYA , HIRATOCHI MASAHIRO , KURAMOCHI YU , ISAJI MASAYUKI , SHIMIZU KAZUO , MIYAGI TAKASHI
IPC分类号： C07H19/052 , A61K31/7056 , A61P13/12 , A61P19/06 , A61P43/00
CPC分类号： C07H19/052
摘要： The invention provides benzimidazole derivatives represented by the general formula (I) or pharmacologically acceptable salts or prodrugs thereof which exhibit inhibitory activities against sodium-dependent nucleoside transporter 2 and are efficacious against diseases caused by abnormality in plasma uric acid level: (I) (wherein n is 1 or 2; R and R are each H, halogeno, cyano, optionally substituted alkyl, optionally substituted aryl, or the like; R is H, halogeno, optionally substituted alkyl, or the like; R and R are each H, halogeno, OH, or the like; R and R are each H or OH; and R is F or OH). The compounds are useful in the prevention or treatment of gout, hyperuricemia, urolithiasis, hyperuricemic nephropathy, and so on.
-
6.发明公开GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES 有权GLUCOPYRANOSYLOXY-BENZYLBENZEN-DERIVATE，MEDIZINISCHE ZUSAMMENSETZUNG UND ZWISCHENPRODUKTEFÜRDIE HERSTELLUNG DER DERIVATE
公开(公告)号：EP1270584A4
公开(公告)日：2003-04-09
申请号：EP01912380
申请日：2001-03-15
发明人： FUJIKURA HIDEKI , FUSHIMI NOBUHIKO , NISHIMURA TOSHIHIRO , TATANI KAZUYA , KATSUNO KENJI , HIRATOCHI MASAHIRO , TOKUTAKE YOSHIKI , ISAJI MASAYUKI
IPC分类号： A61K31/7034 , A61P3/04 , A61P3/10 , A61P43/00 , C07C39/04 , C07C69/16 , C07C69/18 , C07C69/78 , C07C323/18 , C07H15/203 , A61K31/70 , C07C39/15
CPC分类号： C07H15/203
摘要： Glucopyranosyloxybenzylbenzene derivatives of the general formula (I) and salts thereof, which exhibit excellent human SGLT2 inhibiting activity and are useful as preventive or therapeutic drugs for diabetes, obesity and so on; and intermediates for the preparation of the derivatives wherein R is hydrogen or hydroxylated lower alkyl; R is lower alkyl, lower alkoxy, lower alkylthio, hydroxylated lower alkyl, hydroxylated lower alkoxy, hydroxylated lower alkylthio, or the like.
摘要翻译： 通式（I）的吡喃葡萄糖基氧基苄基苯衍生物及其盐，其显示优异的人SGLT2抑制活性，并可用作糖尿病，肥胖等的预防或治疗药物; 和用于制备其中R 1是氢或羟基化的低级烷基的衍生物的中间体; R 2是低级烷基，低级烷氧基，低级烷硫基，羟基化的低级烷基，羟基化的低级烷氧基，羟基化的低级烷硫基等。
-
7.发明公开GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF 有权Glucopyranosyloxypyrazole衍生物，药物遏制和中间产品及其
公开(公告)号：EP1213296A4
公开(公告)日：2002-09-04
申请号：EP00954963
申请日：2000-08-24
发明人： FUJIKURA HIDEKI , NISHIMURA TOSHIHIRO , KATSUNO KENJI , HIRATOCHI MASAHIRO , IYOBE AKIRA , FUJIOKA MINORU , ISAJI MASAYUKI
IPC分类号： A61K31/7056 , A61P3/04 , A61P3/10 , C07D231/20 , C07H17/02
CPC分类号： C07D231/20 , C07H17/02 , Y10S514/866 , Y10S514/909
摘要： Glucopyranosyloxypyrazole derivatives represented by general formula (I), which have an effect of inhibiting human SGLT2 activity and are useful as preventives or remedies for diabetes, complication of diabetes or obesity, or pharmacologically acceptable salts thereof. In said formula, R1 represents hydrogen or lower alkyl; one of Q?1 and T1¿ represents a group of formula (A), while the other represents lower alkyl or halogenated lower alkyl; and R2 represents hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogenated lower alkyl or halogeno.
摘要翻译： 本发明涉及衍生物glucopyranosyloxypyrazole由通式表示：
worin - [R <1> darstellt一个氢原子或一个低级烷基; Q的一个<1>和T <1> darstellt由通式表示的基团： 而另一个darstellt低级烷基或卤代（低级烷基）基团; 且R <2> darstellt氢原子，低级烷基，低级烷氧基，低级烷硫基，卤代（低级烷基）基团或卤原子，或其药学上可接受的盐，其具有对人抑制活性 SGLT2并可用作预防或治疗糖尿病，糖尿病并发症或肥胖症的，药剂和药物组合物，其包括相同的和其中间体是有用的。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.009 秒)
